董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yosef Rauch | 男 | Chairman of the Board | 69 | 72.60万美元 | 15513.02 | 2026-03-12 |
| Shai Meretzki | 男 | Chief Executive Officer and Director | 57 | 98.30万美元 | 41909.11 | 2026-03-12 |
| Gil Shapira | 男 | Independent Director | 67 | 未披露 | 842.77 | 2026-03-12 |
| Alon Ariel | 男 | Independent Director | 60 | 未披露 | 85.63 | 2026-03-12 |
| Margalit Assayag | 女 | Independent Director | 62 | 未披露 | 85.63 | 2026-03-12 |
| Benjamin Shafir | 男 | Independent Director | 76 | 未披露 | 85.63 | 2026-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shai Meretzki | 男 | Chief Executive Officer and Director | 57 | 98.30万美元 | 41909.11 | 2026-03-12 |
| Meital Enbar | 女 | VP Finance | 47 | 14.60万美元 | 82.50 | 2026-03-12 |
| Dror Ben David | 男 | Chief Operations Officer | 49 | 20.30万美元 | 847.25 | 2026-03-12 |
董事简历
中英对照 | 中文 | 英文- Yosef Rauch
-
Yosef Rauch，自2012年4月起担任Bonus BioGroup Ltd.董事会主席。从1985年到1989年，劳赫先生担任以色列当时最大的共同基金公司Leumi PIA的首席经济学家和经济部经理。从1989年到1991年，Rauch先生担任国际贸易公司集团Koor-Trade的财务部经理。自1992年以来，Rauch先生一直在以色列和国外担任资本市场顾问，并一直活跃于医疗设备和软件企业家的行列。Rauch先生拥有特拉维夫大学金融与会计和计算机与信息系统工商管理硕士学位以及巴伊兰大学经济学和工商管理学士学位。
Yosef Rauch has served as the Chairman of board of directors since April 2012. From 1985 to 1989, Mr. Rauch served as Chief Economist and Manager of the Economics Department of Leumi PIA, Israel's then largest largest mutual fund company. From 1989 to 1991 Mr. Rauch served as the manager of the treasury department of Koor Trade, a group of international trade companies. Since 1992, Mr. Rauch has served as a capital markets consultant in Israel and abroad and has been active as a medical device and software entrepreneur. Mr. Rauch holds an M.B.A. in Finance & Accounting and Computers & Information Systems from the Tel Aviv University and a B.A. in Economics and Biness Administration from Bar Ilan University. - Yosef Rauch，自2012年4月起担任Bonus BioGroup Ltd.董事会主席。从1985年到1989年，劳赫先生担任以色列当时最大的共同基金公司Leumi PIA的首席经济学家和经济部经理。从1989年到1991年，Rauch先生担任国际贸易公司集团Koor-Trade的财务部经理。自1992年以来，Rauch先生一直在以色列和国外担任资本市场顾问，并一直活跃于医疗设备和软件企业家的行列。Rauch先生拥有特拉维夫大学金融与会计和计算机与信息系统工商管理硕士学位以及巴伊兰大学经济学和工商管理学士学位。
- Yosef Rauch has served as the Chairman of board of directors since April 2012. From 1985 to 1989, Mr. Rauch served as Chief Economist and Manager of the Economics Department of Leumi PIA, Israel's then largest largest mutual fund company. From 1989 to 1991 Mr. Rauch served as the manager of the treasury department of Koor Trade, a group of international trade companies. Since 1992, Mr. Rauch has served as a capital markets consultant in Israel and abroad and has been active as a medical device and software entrepreneur. Mr. Rauch holds an M.B.A. in Finance & Accounting and Computers & Information Systems from the Tel Aviv University and a B.A. in Economics and Biness Administration from Bar Ilan University.
- Shai Meretzki
-
Shai Meretzki，自2012年4月起担任Bonus BioGroup Ltd.首席执行官和董事。Meretzki博士于2008年7月创立了这家子公司，自成立以来一直担任其首席执行官。Meretzki博士在生命科学公司拥有丰富的运营、管理和领导经验。2002年，Meretzki博士创立了Pluristem Therapeutics Inc.（现称为Pluri Inc.）（纳斯达克：PLUR；TASE：PLUR），并担任其首席执行官和首席技术官至2008年。Meretzki博士还担任以色列私营公司Biological Industries Israel Beit-Haemek Ltd.的董事会主席。Meretzki博士拥有与以色列魏茨曼科学研究所合作的Technion生物技术博士学位。
Shai Meretzki has served as Chief Executive Officer and as a director since April 2012. Dr. Meretzki founded the Subsidiary in July 2008 and has served as its Chief Executive Officer since its incorporation. Dr. Meretzki has extensive operational, management and leadership experience in life science companies. In 2002, Dr. Meretzki founded Pluristem Therapeutics Inc. (now known as Pluri Inc.) (Nasdaq: PLUR; TASE: PLUR) and served as its Chief Executive Officer and Chief Technology Officer until 2008. Dr. Meretzki also served as the chairman of the board of directors of Biological Indtries Israel Beit Haemek Ltd., an Israeli private company, until 2021, and as a member of the board of directors of Sartori Israel Ltd. until June 2024. Dr. Meretzki holds a Ph.D. in biotechnology from Technion in cooperation with the izmann Institute of Science, Israel. - Shai Meretzki，自2012年4月起担任Bonus BioGroup Ltd.首席执行官和董事。Meretzki博士于2008年7月创立了这家子公司，自成立以来一直担任其首席执行官。Meretzki博士在生命科学公司拥有丰富的运营、管理和领导经验。2002年，Meretzki博士创立了Pluristem Therapeutics Inc.（现称为Pluri Inc.）（纳斯达克：PLUR；TASE：PLUR），并担任其首席执行官和首席技术官至2008年。Meretzki博士还担任以色列私营公司Biological Industries Israel Beit-Haemek Ltd.的董事会主席。Meretzki博士拥有与以色列魏茨曼科学研究所合作的Technion生物技术博士学位。
- Shai Meretzki has served as Chief Executive Officer and as a director since April 2012. Dr. Meretzki founded the Subsidiary in July 2008 and has served as its Chief Executive Officer since its incorporation. Dr. Meretzki has extensive operational, management and leadership experience in life science companies. In 2002, Dr. Meretzki founded Pluristem Therapeutics Inc. (now known as Pluri Inc.) (Nasdaq: PLUR; TASE: PLUR) and served as its Chief Executive Officer and Chief Technology Officer until 2008. Dr. Meretzki also served as the chairman of the board of directors of Biological Indtries Israel Beit Haemek Ltd., an Israeli private company, until 2021, and as a member of the board of directors of Sartori Israel Ltd. until June 2024. Dr. Meretzki holds a Ph.D. in biotechnology from Technion in cooperation with the izmann Institute of Science, Israel.
- Gil Shapira
-
Gil Shapira，自2012年4月起担任Bonus BioGroup Ltd.董事会成员。Shapira先生是ProPharma Ltd.的创始人和首席执行官，ProPharma Ltd.是一家多学科的设计、建造和咨询公司，专门从事制药、生物技术和生命科学行业。1999年至2016年，夏皮拉先生担任A.D. Clean Rooms Engineering Ltd.的首席执行官，该公司是一家专门从事无尘室设计、建造和验证的公司。夏皮拉先生拥有纽约布鲁克林布鲁克林理工学院工业管理学士学位。
Gil Shapira has served on board of directors since April 2012. Since 2017, Mr. Shapira has served as a founder and the Chief Executive Officer of ProPharma Ltd., a multi disciplinary design, construction and consultancy company specializing in the pharmaceutical, biotechnology and life science indtries, since 2021, Mr. Shapira has served as the Chief Executive Office of Cannado Ltd , an indoor cultivation farm specializing in the growth and propagation of medical cannabis and, since February 2025, Mr. Shapira serves as the Chief Executive Officer of Cantek Ltd. (Formosa Ltd. has agreed to acquire Cantek Ltd.), a company involved in the manufacturing, storage, and distribution of medical cannabis products. Mr. Shapira is also a co founder and partner at Five Q Ltd (Q5), a firm specializing in the design, construction, and maintenance of cleanrooms and high containment laboratories for sensitive indtries. From 2002 to 2016, Mr. Shapira served as the Chief Executive Officer of A.D. Clean Rooms Engineering Ltd., a company specializing in the design, construction and validation of clean rooms. Mr. Shapira studied Indtrial Management at the Polytechnic Brooklyn Institute, Brooklyn, New York. - Gil Shapira，自2012年4月起担任Bonus BioGroup Ltd.董事会成员。Shapira先生是ProPharma Ltd.的创始人和首席执行官，ProPharma Ltd.是一家多学科的设计、建造和咨询公司，专门从事制药、生物技术和生命科学行业。1999年至2016年，夏皮拉先生担任A.D. Clean Rooms Engineering Ltd.的首席执行官，该公司是一家专门从事无尘室设计、建造和验证的公司。夏皮拉先生拥有纽约布鲁克林布鲁克林理工学院工业管理学士学位。
- Gil Shapira has served on board of directors since April 2012. Since 2017, Mr. Shapira has served as a founder and the Chief Executive Officer of ProPharma Ltd., a multi disciplinary design, construction and consultancy company specializing in the pharmaceutical, biotechnology and life science indtries, since 2021, Mr. Shapira has served as the Chief Executive Office of Cannado Ltd , an indoor cultivation farm specializing in the growth and propagation of medical cannabis and, since February 2025, Mr. Shapira serves as the Chief Executive Officer of Cantek Ltd. (Formosa Ltd. has agreed to acquire Cantek Ltd.), a company involved in the manufacturing, storage, and distribution of medical cannabis products. Mr. Shapira is also a co founder and partner at Five Q Ltd (Q5), a firm specializing in the design, construction, and maintenance of cleanrooms and high containment laboratories for sensitive indtries. From 2002 to 2016, Mr. Shapira served as the Chief Executive Officer of A.D. Clean Rooms Engineering Ltd., a company specializing in the design, construction and validation of clean rooms. Mr. Shapira studied Indtrial Management at the Polytechnic Brooklyn Institute, Brooklyn, New York.
- Alon Ariel
-
Alon Ariel，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。他自2020年起担任Milouot Ltd.的首席执行官，并在2009年至2020年期间担任Biological Industries Ltd.的首席执行官。他此前曾担任Beit Haemek Economic and Development Company 2000 Ltd.的业务经理。此外，Ariel先生是Beit Haemek Economical & Development 2000 Company Ltd.和Biological Industries Ltd.的董事会成员。Ariel先生在斯图加特Berufsakademie获得机械工程师资格，并在以色列开放大学获得化学和管理学士学位，在工程技术中心获得塑料工程学位。他还毕业于TZOR学院、TZOR工业重点岗位学校和特芬工业园。
Alon Ariel has served on board of directors since September 2020. He has served as the chief executive officer of Milouot Ltd. since 2020 and, beten 2009 and 2020, he served as the chief executive officer of Biological Indtries Ltd. He previoly served as a biness manager of Beit Haemek Economic and Development Company 2000 Ltd. In addition, in the past several years he has served as a member of the board of directors of Beit Haemek Economical & Development 2000 Company Ltd. and Biological Indtries Ltd. Mr. Ariel qualified as a mechanical engineer at Berufsakademie, Stuttgart, and received his B.A. in chemistry and management from the Open University of Israel and his degree in plastics engineering from the Center for Engineering and Technology. He also graduated from Tzor College, the Tzor School for key posts in indtry and the Tefen Indtrial Park. - Alon Ariel，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。他自2020年起担任Milouot Ltd.的首席执行官，并在2009年至2020年期间担任Biological Industries Ltd.的首席执行官。他此前曾担任Beit Haemek Economic and Development Company 2000 Ltd.的业务经理。此外，Ariel先生是Beit Haemek Economical & Development 2000 Company Ltd.和Biological Industries Ltd.的董事会成员。Ariel先生在斯图加特Berufsakademie获得机械工程师资格，并在以色列开放大学获得化学和管理学士学位，在工程技术中心获得塑料工程学位。他还毕业于TZOR学院、TZOR工业重点岗位学校和特芬工业园。
- Alon Ariel has served on board of directors since September 2020. He has served as the chief executive officer of Milouot Ltd. since 2020 and, beten 2009 and 2020, he served as the chief executive officer of Biological Indtries Ltd. He previoly served as a biness manager of Beit Haemek Economic and Development Company 2000 Ltd. In addition, in the past several years he has served as a member of the board of directors of Beit Haemek Economical & Development 2000 Company Ltd. and Biological Indtries Ltd. Mr. Ariel qualified as a mechanical engineer at Berufsakademie, Stuttgart, and received his B.A. in chemistry and management from the Open University of Israel and his degree in plastics engineering from the Center for Engineering and Technology. He also graduated from Tzor College, the Tzor School for key posts in indtry and the Tefen Indtrial Park.
- Margalit Assayag
-
Margalit Assayag，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。自2009年起，她担任非营利性社会学习项目“每个学生的密码”的首席执行官。Assayag女士在决策层关键职位的管理和指挥方面拥有30多年的经验，重点是以色列国防军和第三部门组织，包括数百万新谢克尔的预算管理、管理人员和雇员的管理、商业发展和创业、组织和实现特定目标、运营和管理复杂项目，包括管理与地方当局、政府部委、公司和商业公司的合同和招标。从2014年到2016年，阿萨亚格夫人一直是能源部石油委员会的成员。Assayag女士拥有Bar Ilan大学经济学和犯罪学学士学位，Ben Gurion大学工商管理MBA学位，Bar Ilan大学董事课程毕业生。
Margalit Assayag has served on board of directors since September 2020. She served as Chief Executive Officer of a non profit social learning project "Password for Every Student" since 2009. Mrs. Assayag has over 30 years of experience in management and command in key positions at decision making level, with an emphasis on the Israeli Defense Forces and third sector organizations, including budget management in NIS millions, management of managers and employees, biness development and entrepreneurship, organization and achievement of specific goals, operation and management of complex projects, including managing contracts and tenders with local authorities, government ministries, corporations and biness companies. Since July 2024, Mrs. Assayag has served as an external director at Blue Wave Capital Ltd. (TASE: BLWV M). From 2014 to 2016, Mrs. Assayag served as a member of the Petroleum Council in the Israeli Ministry of Energy. Mrs. Assayag holds a B.A. degree in Economics and Criminology from Bar Ilan University, and an MBA degree in Biness Administration from Ben Gurion University, and is a graduate of University of Bar Ilan's Directors Cse. - Margalit Assayag，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。自2009年起，她担任非营利性社会学习项目“每个学生的密码”的首席执行官。Assayag女士在决策层关键职位的管理和指挥方面拥有30多年的经验，重点是以色列国防军和第三部门组织，包括数百万新谢克尔的预算管理、管理人员和雇员的管理、商业发展和创业、组织和实现特定目标、运营和管理复杂项目，包括管理与地方当局、政府部委、公司和商业公司的合同和招标。从2014年到2016年，阿萨亚格夫人一直是能源部石油委员会的成员。Assayag女士拥有Bar Ilan大学经济学和犯罪学学士学位，Ben Gurion大学工商管理MBA学位，Bar Ilan大学董事课程毕业生。
- Margalit Assayag has served on board of directors since September 2020. She served as Chief Executive Officer of a non profit social learning project "Password for Every Student" since 2009. Mrs. Assayag has over 30 years of experience in management and command in key positions at decision making level, with an emphasis on the Israeli Defense Forces and third sector organizations, including budget management in NIS millions, management of managers and employees, biness development and entrepreneurship, organization and achievement of specific goals, operation and management of complex projects, including managing contracts and tenders with local authorities, government ministries, corporations and biness companies. Since July 2024, Mrs. Assayag has served as an external director at Blue Wave Capital Ltd. (TASE: BLWV M). From 2014 to 2016, Mrs. Assayag served as a member of the Petroleum Council in the Israeli Ministry of Energy. Mrs. Assayag holds a B.A. degree in Economics and Criminology from Bar Ilan University, and an MBA degree in Biness Administration from Ben Gurion University, and is a graduate of University of Bar Ilan's Directors Cse.
- Benjamin Shafir
-
Benjamin Shafir，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。Shafir先生目前是柳井集团的合伙人，自柳井集团成立以来，他一直在该集团任职。他在与以色列经济中的公司和组织合作方面拥有超过30年的经验和深刻的洞察力，包括在大型上市公司担任高级经济学家。他擅长商业战略，在领导谈判过程、并购、企业估值、担保融资等多个领域的复杂经济过程方面经验丰富。在过去五年中，他曾在以下私营公司担任董事：Yanai Information Resources Ltd.、Matan Meitar Ltd.、Matan EAP Ltd.、Agro Project Ltd.、Yanai Peleg Ltd.，并于2017年至2018年在Poliron Ltd.担任董事会主席。他目前担任Orbit Technologies Ltd.（TASE：ORBI）的外部董事，2011年至2019年担任Raval ACS Ltd（TASE：RVL）的外部董事。Shafir先生拥有希伯来大学经济学和心理学学士学位。
Benjamin Shafir has served on board of directors since September 2020. Mr. Shafir is currently a partner in the Yanai Group, where he has served since its inception. He has over 30 years of experience and deep insight working with companies and organizations throughout the Israeli economy, including as a senior economist in large publicly traded companies. He specializes in biness strategy and is experienced in leading complex economic processes in vario areas, such as negotiation processes, mergers and acquisitions, enterprise valuation, and securing finance. In the past several years he has served as a director at the following private companies: Yanai Information Recses Ltd., Matan Meitar Ltd., Matan EAP Ltd., Agro Project Ltd., and Yanai Peleg Ltd. He currently serves as an external director of Orbit Technologies Ltd. (TASE: ORBI), and from 2011 to 2019 he served as an external director at Raval ACS Ltd (TASE: RVL). Mr. Shafir holds a B.A. in economics and psychology from the Hebrew University. - Benjamin Shafir，自2020年9月起担任Bonus BioGroup Ltd.董事会成员。Shafir先生目前是柳井集团的合伙人，自柳井集团成立以来，他一直在该集团任职。他在与以色列经济中的公司和组织合作方面拥有超过30年的经验和深刻的洞察力，包括在大型上市公司担任高级经济学家。他擅长商业战略，在领导谈判过程、并购、企业估值、担保融资等多个领域的复杂经济过程方面经验丰富。在过去五年中，他曾在以下私营公司担任董事：Yanai Information Resources Ltd.、Matan Meitar Ltd.、Matan EAP Ltd.、Agro Project Ltd.、Yanai Peleg Ltd.，并于2017年至2018年在Poliron Ltd.担任董事会主席。他目前担任Orbit Technologies Ltd.（TASE：ORBI）的外部董事，2011年至2019年担任Raval ACS Ltd（TASE：RVL）的外部董事。Shafir先生拥有希伯来大学经济学和心理学学士学位。
- Benjamin Shafir has served on board of directors since September 2020. Mr. Shafir is currently a partner in the Yanai Group, where he has served since its inception. He has over 30 years of experience and deep insight working with companies and organizations throughout the Israeli economy, including as a senior economist in large publicly traded companies. He specializes in biness strategy and is experienced in leading complex economic processes in vario areas, such as negotiation processes, mergers and acquisitions, enterprise valuation, and securing finance. In the past several years he has served as a director at the following private companies: Yanai Information Recses Ltd., Matan Meitar Ltd., Matan EAP Ltd., Agro Project Ltd., and Yanai Peleg Ltd. He currently serves as an external director of Orbit Technologies Ltd. (TASE: ORBI), and from 2011 to 2019 he served as an external director at Raval ACS Ltd (TASE: RVL). Mr. Shafir holds a B.A. in economics and psychology from the Hebrew University.
高管简历
中英对照 | 中文 | 英文- Shai Meretzki
Shai Meretzki，自2012年4月起担任Bonus BioGroup Ltd.首席执行官和董事。Meretzki博士于2008年7月创立了这家子公司，自成立以来一直担任其首席执行官。Meretzki博士在生命科学公司拥有丰富的运营、管理和领导经验。2002年，Meretzki博士创立了Pluristem Therapeutics Inc.（现称为Pluri Inc.）（纳斯达克：PLUR；TASE：PLUR），并担任其首席执行官和首席技术官至2008年。Meretzki博士还担任以色列私营公司Biological Industries Israel Beit-Haemek Ltd.的董事会主席。Meretzki博士拥有与以色列魏茨曼科学研究所合作的Technion生物技术博士学位。
Shai Meretzki has served as Chief Executive Officer and as a director since April 2012. Dr. Meretzki founded the Subsidiary in July 2008 and has served as its Chief Executive Officer since its incorporation. Dr. Meretzki has extensive operational, management and leadership experience in life science companies. In 2002, Dr. Meretzki founded Pluristem Therapeutics Inc. (now known as Pluri Inc.) (Nasdaq: PLUR; TASE: PLUR) and served as its Chief Executive Officer and Chief Technology Officer until 2008. Dr. Meretzki also served as the chairman of the board of directors of Biological Indtries Israel Beit Haemek Ltd., an Israeli private company, until 2021, and as a member of the board of directors of Sartori Israel Ltd. until June 2024. Dr. Meretzki holds a Ph.D. in biotechnology from Technion in cooperation with the izmann Institute of Science, Israel.- Shai Meretzki，自2012年4月起担任Bonus BioGroup Ltd.首席执行官和董事。Meretzki博士于2008年7月创立了这家子公司，自成立以来一直担任其首席执行官。Meretzki博士在生命科学公司拥有丰富的运营、管理和领导经验。2002年，Meretzki博士创立了Pluristem Therapeutics Inc.（现称为Pluri Inc.）（纳斯达克：PLUR；TASE：PLUR），并担任其首席执行官和首席技术官至2008年。Meretzki博士还担任以色列私营公司Biological Industries Israel Beit-Haemek Ltd.的董事会主席。Meretzki博士拥有与以色列魏茨曼科学研究所合作的Technion生物技术博士学位。
- Shai Meretzki has served as Chief Executive Officer and as a director since April 2012. Dr. Meretzki founded the Subsidiary in July 2008 and has served as its Chief Executive Officer since its incorporation. Dr. Meretzki has extensive operational, management and leadership experience in life science companies. In 2002, Dr. Meretzki founded Pluristem Therapeutics Inc. (now known as Pluri Inc.) (Nasdaq: PLUR; TASE: PLUR) and served as its Chief Executive Officer and Chief Technology Officer until 2008. Dr. Meretzki also served as the chairman of the board of directors of Biological Indtries Israel Beit Haemek Ltd., an Israeli private company, until 2021, and as a member of the board of directors of Sartori Israel Ltd. until June 2024. Dr. Meretzki holds a Ph.D. in biotechnology from Technion in cooperation with the izmann Institute of Science, Israel.
- Meital Enbar
Meital Enbar，自2024年12月起担任Bonus BioGroup Ltd.财务副总裁。2021年至2024年，她担任Bonus Biogroup Ltd.的控制人。在加入Bonus Biogroup之前，Enbar女士于2019年至2021年担任Starplast的控制人，并于2008年至2019年担任Ham-Let Group（以色列-加拿大）子公司的控制人。从2006年到2008年，Enbar女士在毕马威国际的成员公司Somekh Chaikin担任经理。Enbar女士是一名注册会计师（CPA）。她拥有拉马特甘法律与商业学术中心会计学学位和海法大学财务管理证书
Meital Enbar has served as VP Finance since December 2024. From 2021 to 2024, she served as a controller at company. Prior to joining Bon Biogroup, Ms. Enbar served as a controller at Starplast from 2019 to 2021 and as a controller of subsidiaries at Ham Let Group (Israel Canada) from 2008 to 2019. From 2006 to 2008, Ms. Enbar worked as a manager at Somekh Chaikin, a member firm of KPMG International. Ms. Enbar is a certified public accountant (CPA). She holds a degree in Accounting from the Academic Center for Law and Biness in Ramat Gan and a certificate in Financial Management from the University of Haifa.- Meital Enbar，自2024年12月起担任Bonus BioGroup Ltd.财务副总裁。2021年至2024年，她担任Bonus Biogroup Ltd.的控制人。在加入Bonus Biogroup之前，Enbar女士于2019年至2021年担任Starplast的控制人，并于2008年至2019年担任Ham-Let Group（以色列-加拿大）子公司的控制人。从2006年到2008年，Enbar女士在毕马威国际的成员公司Somekh Chaikin担任经理。Enbar女士是一名注册会计师（CPA）。她拥有拉马特甘法律与商业学术中心会计学学位和海法大学财务管理证书
- Meital Enbar has served as VP Finance since December 2024. From 2021 to 2024, she served as a controller at company. Prior to joining Bon Biogroup, Ms. Enbar served as a controller at Starplast from 2019 to 2021 and as a controller of subsidiaries at Ham Let Group (Israel Canada) from 2008 to 2019. From 2006 to 2008, Ms. Enbar worked as a manager at Somekh Chaikin, a member firm of KPMG International. Ms. Enbar is a certified public accountant (CPA). She holds a degree in Accounting from the Academic Center for Law and Biness in Ramat Gan and a certificate in Financial Management from the University of Haifa.
- Dror Ben David
Dror Ben David，自2022年12月起担任Bonus Biogroup Ltd.首席运营官，在此之前，自2012年12月起担任Bonus Biogroup Ltd.研发副总裁。Ben-David博士领导了Bonus Biogroup Ltd.所有候选产品的开发。在加入Bonus BioGroup Ltd.公司之前，Ben David博士曾于2011年至2012年担任Technion肌肉骨骼组织工程实验室的经理。Ben David博士拥有Technion医学院的医学科学博士学位，他的主要专长领域是成体干细胞。
Dror Ben David has served as Chief Operations Officer since December 2022 and prior to that served as VP Research and Development since December 2012. Dr. Ben David has led the development of all of product candidates. Prior to joining Company, Dr. Ben David served as the manager of the Technion Mculoskeletal Tissue Engineering Lab from 2011 to 2012. Dr. Ben David holds a Ph.D. degree in medical sciences from the Technion Faculty of Medicine, and his main field of expertise is adult stem cells.- Dror Ben David，自2022年12月起担任Bonus Biogroup Ltd.首席运营官，在此之前，自2012年12月起担任Bonus Biogroup Ltd.研发副总裁。Ben-David博士领导了Bonus Biogroup Ltd.所有候选产品的开发。在加入Bonus BioGroup Ltd.公司之前，Ben David博士曾于2011年至2012年担任Technion肌肉骨骼组织工程实验室的经理。Ben David博士拥有Technion医学院的医学科学博士学位，他的主要专长领域是成体干细胞。
- Dror Ben David has served as Chief Operations Officer since December 2022 and prior to that served as VP Research and Development since December 2012. Dr. Ben David has led the development of all of product candidates. Prior to joining Company, Dr. Ben David served as the manager of the Technion Mculoskeletal Tissue Engineering Lab from 2011 to 2012. Dr. Ben David holds a Ph.D. degree in medical sciences from the Technion Faculty of Medicine, and his main field of expertise is adult stem cells.